Table 3.
Model | Dose/Administration Route | Exposure Time | Technique | Damage | References |
---|---|---|---|---|---|
Aflatoxin | |||||
Caco-2 cells | AFB1: 1–50 μM | 24 h | Alamar blue assay | Decrease cell viability | [77] |
Caco-2 cells | AFB1: 0.01–1 μg/mL AFM1: 0.01–1 μg/mL |
24, 48, 72 h | MTT assay | AFB1: decrease cell viability AFM1: decrease cell viability |
[78] |
Caco-2 cells | AFB1: 4 μg/mL AFM1: 4 μg/mL |
24 h | MTT assay | AFB1: decrease cell viability AFM1: decrease cell viability |
[79] |
Caco-2 cells | AFM1: 0.0005–4 μg/mL | 48 h | RNA-Seq, CCK-8 assay, Flow cytometry analysis |
No effect on cell viability Induce cell cycle arrest |
[80] |
Caco-2/HT29-MTX cells | AFM1: 0.05, 4 μg/mL | 48 h | CCK-8 assay | Decrease cell viability | [43] |
Ochratoxin A | |||||
Caco-2/HT29-MTX cells | OTA: 0.05, 4 μg/mL | 48 h | CCK-8 assay | Decrease cell viability | [43] |
IPEC-J2 Cells | OTA: 0.5–32 μM | 6, 12, 24 h | MTT assay | Decrease cell viability | [81] |
Caco-2 cells | OTA: 0.1–30 μM | 24 h | RNA-Seq, CCK-8 assay, Flow cytometry analysis |
Decrease cell viability Arrest cell cycle in G2/M phase Induce apoptosis |
[82] |
Caco-2 cells | OTA: 0.0005–4 μg/mL | 48 h | RNA-Seq, Flow cytometry analysis |
Induce cell apoptosis | [83] |
Caco-2 cells | OTA: 0.5–160 μM | 48 h | MTS assay | Decrease cell viability | [84] |
Deoxynivalenol | |||||
Caco-2 cells | DON: 0.25–30 μM | 48 h | MTS assay | Decrease cell viability | [84] |
HT-29 cells | DON: 125–2000 ng/mL | 24 h | Western blot analysis | Induce cell apoptosis | [24] |
IEC-6 cells | DON: 0.5–80 μM | 24 h | Propidium iodide staining | Induce cell apoptosis | [85] |
IPEC-J2 Cells | DON: 200, 2000 ng/mL | 24, 48, 72 h | BrdU incorporation assay, Western blot analysis |
Decrease cell viability Induce cell apoptosis |
[86] |
IPEC-1 cells, IPEC-J2 Cells | DON: 100–4000 ng/mL | 24, 48, 72 h | MTT assay | Decrease cell viability | [87] |
IPEC-J2 Cells | DON: 1–20 μg/mL | 72 h | Flow cytometry analysis | Decrease cell viability Induce cell apoptosis |
[88] |
Zearalenone | |||||
IPEC-J2 Cells | ZEN: 40 μM | 24 h | CCK-8 assay, Flow cytometry analysis, RNA-Seq |
Decrease cell viability Arrest cell cycle in the G2/M phase |
[89] |
IPEC-J2 cells | ZEN: 6, 8 μg/mL | 12–48 h | MTT assay, PCR |
Decrease cell viability Induce cell apoptosis |
[90] |
IPEC-1 cells | ZEN: 0.1–100 μM | 24 h | XTT assay, Microarray assay |
Decrease cell viability | [91] |
HCT116 cells | ZEN: 0–320 μM | 48 h | Methylene blue staining assay | Increase cell viability at very low concentrations, decrease cell viability at high concentrations | [92] |
Fumonisin B1 | |||||
HT-29 cells | FB1: 1.1–69 μM | 72 h | MTT assay | Decrease cell viability | [93] |
Patulin | |||||
Caco-2 cells | PAT: 1–150 μM | 24 h | MTT assay | Decrease cell viability | [94] |
Caco-2 cells | PAT: 0.7–18 μM | 24 h | MTT assay | Decrease cell viability | [95] |
HCT116 cells | PAT: 5–25 μM | 24 h | FDA assay, Western blot analysis |
Decrease cell viability Induce cell apoptosis |
[96] |
HCT116 cells | PAT: 1.25–20 μM | 1–4 days, 24 h | MTT assay, Western blot analysis |
Decrease cell viability Induce apoptotic cells death |
[97] |
Citrinin | |||||
HCT116 cells | CTN: 150 μM | 24 h | MTT assay | Decrease cell viability | [98] |